Abbott Japan Opens Katsuyama Factory Base For Established Pharmaceutical Production
This article was originally published in PharmAsia News
Anton Herbig, divisional vice president for global manufacturing at Abbott, recently introduced the company’s Katsuyama facilities in Fukui prefecture as the main base for providing established pharmaceuticals to the Japan market.
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.